For instance, Gandhi et al. reported a case of lung adenocarcinoma harboring high-level wild-type RET amplification (22–28 copies), without other known oncogenic alterations, that responded to selpercatinib with confirmed systemic and intracranial responses. Here, RET is linked to lung adenocarcinoma.